Annual Drug Patent Expirations for OPANA+ER
Opana Er is a drug marketed by Endo Pharms and is included in two NDAs. There are five patents protecting this drug and six Paragraph IV challenges.
Drug patent litigation for OPANA ER.
This drug has one hundred and sixty-nine patent family members in thirty-two countries.
The generic ingredient in OPANA ER is oxymorphone hydrochloride. Additional details are available on the oxymorphone hydrochloride profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
